No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PGNY240517C40000
- 0.02
- -0.01-33.33%
15min DelayClose May 13 10:35 ET
0.02High0.02Low
0.02Open0.03Pre Close1 Volume221 Open Interest40.00Strike Price2.00Turnover157.74%IV46.06%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.02Time Value100Contract SizeAmericanOptions Type0.0134Delta0.0076Gamma1370.00Leverage Ratio-0.0143Theta0.0000Rho18.30Eff Leverage0.0010Vega
Intraday
- 5D
- 1D
News
Progyny Price Target Cut to $30.00/Share From $48.00 by Barclays
Progyny Price Target Cut to $30.00/Share From $48.00 by Barclays
Progyny Is Maintained at Overweight by Barclays
Progyny Is Maintained at Overweight by Barclays
Barclays Maintains Overweight on Progyny, Lowers Price Target to $30
Barclays analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and lowers the price target from $48 to $30.
Progyny (NASDAQ:PGNY) Has More To Do To Multiply In Value Going Forward
Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Progyny (PGNY)
Fertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'
On Thursday, Progyny Inc (NASDAQ:PGNY) reported first-quarter sales of $278.1 million, up 7.6% year over year, missing the consensus of $289.46 million, primarily due to the increased number of client